diet pills

FDA Rejects Orexigen's New Diet Drug Over Heart Concerns

In a surprise move Tuesday, the FDA rejected Orexigen's proposed new diet drug Contrave, saying the company needed to run another study of its cardiovascular risks. With this rejection, all three of a slate of similar diet drugs from competing pharmaceuticals have been turned back by the agency.

Vivus Shares Rally on Hopes Obesity Drug Will Gain Approval Next Year

Vivus shares are soaring this morning, even though the U.S. Food and Drug Administration rejected the drugmaker's obesity drug Qnexa yesterday. Investors are hoping that the FDA's rejection, which includes a request for more safety data -- not another clinical trial -- will lead to approval next year.

Abbott Pulls Weight Loss Drug Meridia from Market

Drug and medical-device maker Abbott Laboratories announced Friday that it will voluntarily withdraw its controversial obesity drug Meridia, (sibutramine) from the U.S. market at the request of the FDA, due to concerns it increases the risk of heart attacks and strokes.

Orexigen Shares Soar on Partnership Deal With Takeda

Orexigen jumped over 25% in premarket trading after announcing an exclusive partnership agreement potentially worth over $1 billion with Japan's Takeda Pharmaceutical to develop and commercialize Contrave, Orexigen's promising obesity drug.